FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发
Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval
2021-10-01
FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发
FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发
Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval
2021-10-01
FDA指导原则:pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发
广东省药学会 · 2021-07-16
中华预防医学会妇女保健分会 · 2021-07-14
梅斯医学MedSci APP
医路相伴,成就大医
学习
58